> Mein DÄ

MEDIZIN: Editorial

Arzneimittelforschung: Marketing vor Evidenz, Umsatz vor Sicherheit

Drug Research: Marketing Before Evidence, Sales Before Safety

Dtsch Arztebl Int 2010; 107(16): 277-8; DOI: 10.3238/arztebl.2010.0277

Klemperer, David

1.	Heres S, Davis J, et al.: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 2006; 163(2): 185–94. MEDLINE
2.	Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig W-D, Lieb K: The financing of drug trials by pharmaceutical companies and its consequences: part 1. a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials [Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen – Teil 1: Qualitative systematische Literaturübersicht zum Einfluss auf Studienergebnisse, -protokoll und -qualität[. Dtsch Arztebl Int 2010; 107(16): 279–85.
3.	Bekelman J E, Li Y, et al.: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289(4): 454–65. MEDLINE
4.	Ewart R, Lausen H, et al.: Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med 2009; 7(6): 542–6. MEDLINE
5.	Topol EJ: Failing the public health – Rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17): 1707–9. MEDLINE
6.	Psaty BM, Kronmal RA: Reporting mortality findings in trials of rofecoxib for alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA 2008; 299(15): 1813–7. MEDLINE
7.	Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking Member. Accessed March 3, 2010.
8.	Nissen SE: Setting the RECORD straight. JAMA 2010; 303(12): 1194–5. MEDLINE
9.	Spielmans G, Parry P: From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Journal of Bioethical Inquiry 2010; 7: 13–29.
10.	Dreier G, Hasselblatt H, Antes G, Schumacher M: Das Deutsche Register Klinischer Studien: Begründung, technische und inhaltliche Aspekte, internationale Einbindung. Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz 2009; 52(4): 463–8. MEDLINE

Zum Artikel

Login

Passwort vergessen?

Registrieren

Eingeloggt als $LOGINEMAIL$